Syngen BiotechLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Syngen BiotechLtd heeft een totaal eigen vermogen van NT$2.2B en een totale schuld van NT$237.7M, wat de schuld-eigenvermogensverhouding op 10.9% brengt. De totale activa en totale passiva bedragen respectievelijk NT$3.0B en NT$818.7M. De EBIT Syngen BiotechLtd is NT$305.1M waardoor de rentedekking 40.9 is. Het heeft contanten en kortetermijnbeleggingen van NT$228.3M.

Belangrijke informatie

10.9%

Verhouding schuld/eigen vermogen

NT$237.73m

Schuld

Rente dekkingsratio	40.9x
Contant	NT$228.31m
Aandelen	NT$2.18b
Totaal verplichtingen	NT$818.68m
Totaal activa	NT$3.00b

Recente financiële gezondheidsupdates

Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?

Mar 25

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Dec 16

Recent updates

Is Syngen Biotech Co., Ltd.'s (GTSM:8279) Latest Stock Performance Being Led By Its Strong Fundamentals?

Jan 14

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Dec 16

Syngen Biotech's (GTSM:8279) Earnings Are Growing But Is There More To The Story?

Nov 25

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NT$1.0B ) 8279 } overtreffen de korte termijn passiva ( NT$471.7M ).

Langlopende schulden: De kortetermijnactiva 8279 ( NT$1.0B ) overtreffen de langetermijnschulden ( NT$346.9M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 0.4% ) 8279 wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 8279 is de afgelopen 5 jaar gedaald van 17.5% naar 10.9%.

Schuldendekking: De schuld van 8279 wordt goed gedekt door de operationele kasstroom ( 143.8% ).

Rentedekking: De rentebetalingen op de schuld van 8279 worden goed gedekt door EBIT ( 40.9 x dekking).

Syngen BiotechLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Recent updates

Third quarter 2024 earnings released: EPS: NT$2.67 (vs NT$2.59 in 3Q 2023)

Second quarter 2024 earnings released: EPS: NT$1.83 (vs NT$2.76 in 2Q 2023)

Investor sentiment deteriorates as stock falls 18%

Upcoming dividend of NT$5.00 per share

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: EPS exceeds analyst expectations

Syngen Biotech Co.,Ltd., Annual General Meeting, May 29, 2024

Third quarter 2023 earnings released: EPS: NT$2.59 (vs NT$3.37 in 3Q 2022)

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of NT$5.00 per share at 2.9% yield

Full year 2022 earnings released: EPS: NT$11.85 (vs NT$8.77 in FY 2021)

No independent directors

Third quarter 2022 earnings released: EPS: NT$3.37 (vs NT$2.54 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$4.00 per share

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

No independent directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS NT$2.54 (vs NT$2.20 in 3Q 2020)

Upcoming dividend of NT$3.50 per share

Second quarter 2021 earnings released: EPS NT$2.25 (vs NT$2.75 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$1.53 (vs NT$1.48 in 1Q 2020)

Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?

Full year 2020 earnings released: EPS NT$7.95 (vs NT$7.86 in FY 2019)

Syngen Biotech Co., Ltd., Annual General Meeting, May 28, 2021

New 90-day high: NT$113

Should Syngen Biotech Co., Ltd. (GTSM:8279) Be Part Of Your Dividend Portfolio?

Did You Miss Syngen Biotech's (GTSM:8279) Impressive 104% Share Price Gain?

Is Syngen Biotech Co., Ltd.'s (GTSM:8279) Latest Stock Performance Being Led By Its Strong Fundamentals?

New 90-day low: NT$107

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Syngen Biotech's (GTSM:8279) Earnings Are Growing But Is There More To The Story?

Third quarter earnings released

New 90-day low: NT$107

First half earnings released

New 90-day high - NT$130

First half earnings released

New 90-day high - NT$120

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven